Introduction
While investigating why variant tumors or infectious agents may fail to stimulate effective immunity in original hosts, we discovered that mice immunized first or dominantly with allogeneic or xenogeneic cells failed to respond with cytolytic T lymphocytes (CTL) to new or different antigens, although antibody responses were unaffected. Furthermore, fresh immune sera given passively to normal mice or added in high dilution to one-way mixed lymphocyte cultures (MLC) suppressed or prevented CTL responses to antigens unrelated to the antigens used for raising immune sera (1, 2) . The possibility that transforming growth factor (TGF)-β might be involved was suggested by earlier observations that active TGF-β alone suppressed various immune responses including CTL responses in vitro (3) , and that an immunogenic cancer transfected to secrete latent TGF-β induced no or very low CTL responses and grew more rapidly and progressively Received 28 July 1997, accepted 4 December 1997 in vivo than control tumors (4) . The idea that TGF-β linked to IgG was responsible for suppression caused by prior immunization was supported by the following observations: (i) IgG purified from fresh immune sera contained small quantities of latent TGF-β, (ii) the capacity of immune sera to suppress was eliminated by adsorptions which removed IgG, and (iii) the capacity of immune sera to suppress was lost by procedures which dissociated TGF-β and IgG or was prevented by a murine mAb directed against active TGF-β (2). Sera containing elevated levels of IgG-TGF-β were obtained either from mice given repeated injections of antigen every 2-4 days (2) or from young MRL/MPJ/lpr mice producing autoantibodies spontaneously (5) . Although only B lymphocytes secrete IgG, many cell types secrete latent TGF-β so that the linkage between IgG and latent TGF-β might occur extracellularly and require various putative cellular and/or soluble factors. On the other hand, if immunized B lymphocytes secreting IgG also secrete IgG-TGF-β, then these cells may suppress CTL responses before threshold levels of circulating or surrounding IgG-TGF-β are obtained. The following experiments support the latter possibility.
Methods

Mice and cell lines
Mice were female, 8-12 weeks old C3H/HeN (MTV -) (H-2 k ) and BALB/c (H-2 d ). Mice were housed in a pathogen-free barrier facility. Target cells for measuring CTL in MLC were P815 (H-2 d ) cells. TR-PRO is a malignant murine tumor transfected to express an allogeneic histocompatibility complex class I gene, K 216 (6) . Mice injected with TR-PRO cells respond with CTL specific for target cells expressing the K 216 gene product; popliteal lymph node (LN) cells of mice challenged in foot pads with TR-PRO were assayed against labeled tumor cells designated 1591-RE which express K 216 .
Immune LN cells
C3H mice under light anesthesia were injected in each hind foot pad with 0.05 ml of a 5.0% suspension of washed sheep red blood cells (SRBC) given on days 0, 2 and 4. Immune cells were obtained on day 6 after injections began except as noted. In all experiments cells were pooled from three or more similarly immunized mice or from two or more normal mice.
IgG-secreting plaque-forming cells (PFC)
Direct (IgM) and indirect (IgG) PFC against SRBC were enumerated in Cumingham chambers (7) using affinity-purified rabbit anti murine IgG for developing IgG PFC.
Hyperimmune serum
Fresh serum pooled from mice injected in hind foot pads twice a week for 11 weeks with SRBC was diluted in RPMI 1:10, fractionated (Ͼ100 kDa) and concentrated to one-third original volumes (2) . Aliquots were stored at -80°C. The reconstituted serum consistently abolished CTL responses when added to fresh MLC at a final dilution in culture of 1:1000. Affinity-purified murine IgG contains latent TGF-β (2) and IgG purified from hyperimmune serum contained~5.0 ng of acid activatible TGF-β (the equivalent of~17 ng of latent TGF-β)/mg IgG measured using the MvlLu (a line of mink lung 'epithelial-like' cells) bioassay. Suppression by hyperimmune serum was eliminated by adsorptions which removed IgG, by acidification at pH 2.0 which dissociated IgG and TGF-β or by antibody to TGF-β. Hyperimmune serum caused no suppression when added to cultures Ͼ24 h after they were set up. Fresh normal sera processed and stored identically caused no suppression of CTL responses when added to fresh MLC at a final dilution in cultures of 1:100.
MLC and assay for cytolytic T cells
Cultures and assay procedures were done as previously described (1, 2 
Antibodies against latent TGF-β
Rabbit antibodies partially purified from sera of rabbits immunized with the simian precursor for TGF-β-1 (P-TGF-β) were a generous gift from Drs Larry E. Gentry and Grainne A. McMahon (Medical College of Ohio, Toledo, OH). The rabbit anti P-TGF-β antibodies (rαP-TGF-β) directed against epitopes on the PRO region of the TGF-β-1 precursor bind the latencyassociated peptide but do not bind to mature active simian TGF-β-1 (8) (9) (10) . Using Western dot blots on filters coated with rαP-TGF-β (10 µg antibody/ml; filters washed and blocked), recombinant murine latent TGF-β was detectable at a concentration of~30 pg/ml; rαP-TGF-β did not bind active porcine or murine TGF-β (100 ng/ml) or high concentrations of BSA or goat IgG.
Detection of latent TGF-β in IgG captured from isolated IgGsecreting B cells
A modification of a method developed for detecting rare foci of mutant IgG secreted by individual B cells (11) was used to detect individual foci of IgG or latent TGF-β present in IgG secreted by isolated PFC. Nitrocellulose membranes (Optitran 0.45 µm) were cut to fit 35ϫ10 mm tissue culture dishes and were coated with F(abЈ) 2 goat anti-murine IgG (gαmIgG) (10 µg/ml); control membranes were coated with normal goat Ig (gIg) (Organon Teknika, West Chester, PA). Membranes were washed and blocked with BSA. Between 10 5 and 10 6 immune LN cells in 150 µl CM with 0.5% FCS were floated over and settled onto the membranes which were then incubated for 2 h at 37°C, 5% CO 2 , 100% humidity; cells were vigorously washed off membranes. Following blocking with 2% milk, replicate test and control membranes were incubated overnight with either 3.0 µg/ml of rabbit anti-murine IgG (rαmIgG) (Calbiochem-Novabiochem, La Jolla, CA), with 1.0 µg/ml rαP-TGF-β or with 3.0 µg/ml affinity-purified rabbit IgG directed against horse spleen ferritin (rαh ferritin) (Sigma, St Louis, MO) which served as a control rabbit antibody. Foci of secreted IgG or latent TGF-β linked to IgG were made visible using goat anti-rabbit IgG conjugated to alkaline phosphatase in a BCIP/NBT substrate containing 5-bromo-4-chloro-3-indolyphosphate p-toluidine and p-nitro blue tetrazolium chloride (R & D Systems, Minneapolis, MN). These conditions for detecting foci of IgG captured from isolated PFC were developed using 1.0 µl microdroplets of serial dilutions of test materials spotted on membranes. The test materials were recombinant latent and active TGF-β, hyperimmune serum and IgG affinity-purified from hyperimmune serum (mIgG). Neither latent nor active TGF-β alone (100 ng/ml) produced spots on test or control membranes developed with any of the rabbit antibodies. Neither hyperimmune serum (dilution 1:10) nor mIgG (1 mg/ml) was detected on membranes coated with control gIg and developed with any of the rabbit antibodies. In contrast, high dilutions of hyperimmune serum or IgG purified from it produced distinct spots or foci on membranes coated with gαmIgG and developed with rαmIgG or rαP-TGF-β but not with rαh ferritin. mIgG was detected in dilutions containing 0.5-1.0 µg IgG/ml; latent TGF-β was detected in dilutions containing~5.0 µg mIgG/ml which had 85 pg of latent TGF-β linked to it. These observations established that with this test system, rαP-TGF-β would only detect latent TGF-β linked to IgG (i.e. latent TGF-β produced by cells other than IgG secreting PFC would not be detected) and that the sensitivity of detection of latent TGF-β linked to IgG approximated the sensitivity of~30 pg/ml of latent TGF-β measured using rαP-TGF-β on Western Dot Blots (see above).
Macrophages
Macrophages were recovered from the peritoneal cavity by injecting normal mice with 5.0 ml of sterile normal saline i.p., gently massaging the abdomen and withdrawing the fluid; the procedure was repeated once. Cells in the aspirated fluid were sedimented and raised in complete medium;~10 6 cells were recovered per donor. Approximately 90% of cells adhere rapidly to plastic, are avidly phagocytic and F4/80 positive.
Other procedures and reagents
The procedures for eliminating adherent cells and Thy-1 ϩ cells from cell suspensions were the same as used previously (2) . Antibody against active TGF-β, a monoclonal mIgG2b, was the same as used previously (2) and was purchased from (Genzyme, Cambridge, MA). Anti-Fc receptor antibody (monoclonal rat anti-mouse FcR, designated 2.4G2) was the same as previously used (2) . Murine latent TGF-β was produced by a murine tumor cell line transfected with cDNA for murine TGF-β-1 (4); supranatant of 48 h cultures of the cells, designated as 7.63, grown in serum-free medium was concentrated and stored at -80°C at a concentration of~100 ng of acid-activatable TGF-β-1/ml as determined using the MvlLu bioassay (12) . Active porcine TGF-β-1 was purchased (R & D Systems).
Results
We reported previously that a first or dominant immunization of mice with alloantigen prevented CTL responses to unrelated allo or tumor antigens (1) . Similarly, mice immunized in hind foot pads with SRBC for 6 days before injection with tumor cells failed to respond with CTL directed against tumor cells (Table 1) . By 6 days after beginning immunization with SRBC, switch from IgM to IgG occurs; popliteal LN cells contain maximum numbers of IgG-secreting PFC and PFC begin to circulate (13, 14) . The following experiments demonstrate that small numbers of IgG secreting PFC obtained from LN at 6 days or more after beginning immunizations with SRBCprevent CTL responses of normal spleen cells in vitro, suggesting that such cells may also prevent CTL responses in vivo. a Three mice in Gr1 were each injected in hind foot pads with 50 µl 10% SRBC on days 0, 2 and 4.
b All mice challenged in hind foot pads with 2 ϫ 10 6 TR-PRO tumor cells suspended in 10% sheep erythrocytes on days 6, 9, 12 and 15.
c PLN cells were assayed on day 17 against 51 Cr-labelled tumor target cells; each result is the mean for three mice assayed in triplicate ϮSD for nine determinations. The 51 Cr release (%) from labelled control tumor target cells (EL-4) was Ͻ10% for all LN cells at all E:T ratios, data not shown.
IgG-secreting PFC prevent CTL responses in MLC
In many repeated experiments, 5ϫ10 4 to 1.5ϫ10 5 immune LN cells obtained 6 days after beginning immunization with SRBC were added to MLC (5ϫ10 5 normal syngeneic responder cells and 5ϫ10 5 irradiated stimulator cells). CTL responses were abolished or markedly suppressed ( Table 2) ; 90% of PFC in suspensions which abolished responses secreted IgG and as few as 300 IgG PFC per culture were sufficient (e.g. Experiment 1 in Table 2 ). LN cells from mice immunized with horse erythrocytes and containing 300 or more IgG-secreting PFC against horse erythrocytes were as effective in preventing CTL responses as PFC against SRBC (data not presented), indicating that suppression caused by PFC was independent of the antigen specificity of the IgG secreted, just as suppression caused by hyperimmune serum was also independent of the antigen specificity of IgG present in the serum (2) .
In a series of experiments, the beginning of injections of SRBC was staggered for groups of mice so that LN cells obtained at 6 days could be compared with LN cells obtained at 4 days (antigen injected on days 0 and 2) and at 5, 8 or l0 days (antigen injected on days 0, 2 and 4). Suspensions of LN cells obtained at 4 days contained large numbers of IgM but no IgG PFC; these 4 day cells caused no suppression (data not shown). Cells obtained on day 5 containing high numbers of IgM but low numbers of IgG PFC caused little or no suppression; whereas, the same number of LN cells obtained on day 6 containing Ͼ300 IgG PFC/10 5 cells abolished responses (e.g. Experiment 2 in Table 2 ). LN cells obtained at 8 or 10 days contained about a half to a third as many IgG PFC as cells obtained at day 6, but dilutions of suspensions which contained numbers of IgG PFC comparable to suspensions obtained at 6 days caused comparable suppression (e.g. Experiment 3 in Table 2 ). In other experiments not presented, mice were immunized twice a week with SRBC for 5-11 weeks. Sera from these mice abolished CTL responses at dilutions of 1:1000 to 1:5000 in MLC and LN cells obtained 2 days after the last injection of SRBC (containing~500 IgG-secreting PFC/10 5 cells added to each culture) abolished CTL responses, indicating that the capabil- Table  2 , cells treated to eliminate adherent cells assayed at the time the cells were added to culture contained~40% more PFC than untreated cells held on ice during the treatment procedure (301 Ϯ 33 versus 217 Ϯ 16 PFC/1.5ϫ10 5 cells), but the fresh LN cells from which they were obtained and assayed at the time of harvest contained more PFC than the treated cells (388 Ϯ 61 versus 301 Ϯ 33 PFC/1.5ϫl0 5 cells). In repeated trials, this rapid loss of PFC occurred whether the cells were treated, held on ice or were cultured, e.g. as shown in the following experiment. LN cells (10 5 ) containing 1200 Ϯ 130 IgG PFC were added to each of 15 replicate MLC; three cultures were harvested for assay of PFC at 3, 24, 48 and 72 h. By 3 h cultures contained only 800 Ϯ 190 IgG PFC per culture and the number dropped to Ͻ100 IgG PFC per culture at each of the later times. CTL responses measured in the remaining three cultures at 96 h were abolished while responses for three control cultures without added PFC caused 65 Ϯ 9% 51 Cr release at an E:T ratio of 50:1. Whether continuing secretion of IgG by the few PFC present in MLC after the first day was necessary for sustaining suppression was not determined; however, the following experiment confirms that loss of secretion of IgG in vitro results in a loss of capacity to suppress CTL responses and that cells secreting IgG must interact early with potentially responding cells to cause suppression.
Three sets of MLC were prepared using freshly obtained normal cells for each set; sets were prepared 12 h before (-12 h), at the time immune LN cells were harvested (0 h) or 12 h later (ϩ12 h). Immune LN cells were obtained from mice 6 days after beginning injections of SRBC in foot pads; 10 5 fresh immune LN cells containing 808 Ϯ 68 PFC were added per culture to the -12 and 0 h sets of MLC. The remaining immune LN cells were cultured, 10 7 cells/ml, under the same conditions as the MLC. Twelve hours later the cultured immune LN cells were re-assayed and, now containing only 260 Ϯ PFC/10 5 cells, were added to the ϩ12 h set. Controls for each set included cultures manipulated in the same way except that fresh medium alone or hyperimmune serum diluted in medium, final concentration 1:1000, was added to cultures. As shown in Table 3 , freshly prepared LN cells abolished CTL responses in fresh (0 h) MLC; interestingly, these LN cells caused no suppression of MLC prepared 12 h previously. As expected from the previous findings, LN cells cultured for 12 h and containing many fewer PFC no longer caused a Three sets of MLC were prepared using freshly obtained cells for each set, 10 5 fresh immune LN cells containing 808 Ϯ 68 IgG-secreting PFC were added per culture to the fresh 0 h set and to the cultures set up 12 h previously (-12 h). The fresh LN cells were cultured for 12 h, reassayed for PFC and added to fresh MLC (ϩ12). Hyperimmune serum was added to give a final dilution in culture of 1:1000. Hyperimmune serum was also added to give a final dilution in culture of 1:1000. Hyperimmune serum was also added to replicate cultures from the 0 h set 24, 48 and 72 h: addition of hyperimmune serum at 24 h reduced responses~50% (30 Ϯ 20% 51 Cr release, E:T of 50:1) but had no effect on responses when added at the later times.
b The numbers recorded are means ϮSD for six replicate cultures for medium and three replicate cultures for additions of immune LN or hyperimmune serum.
suppression in the fresh ϩ12 h set of MLC. The findings were consistent with the idea that PFC interacting early with potentially responding cells of 0 h set were effective but such cell-cell interaction was prevented in the already interacting cells in the -12 h set. The finding that hyperimmune serum prevented responses in all three sets suggests that interaction of PFC with responding cells is not necessary for suppression once threshold levels of circulating or surrounding IgG-TGF-β are attained.
Macrophages and Fc receptors are required for suppression caused by PFC
Resident resting macrophages present in normal spleen responder cells and functional Fc receptors were required for suppression of CTL responses caused by hyperimmune serum (2). Macrophages were similarly required for suppression caused by small numbers of IgG-secreting PFC using normal or immune spleen cells. However, paradoxically, 5ϫ10 5 LN cells from mice immunized with SRBC, regardless of the number of IgG-secreting PFC they contained, responded in MLC as well as 5ϫ10 5 normal spleen cells, even though small numbers (1ϫ10 5 ) of these same immune LN cells abolished CTL responses of 5ϫ10 5 normal spleen cells (e.g. Experiment 1 in Table 4 ). However, as shown in Experiment 2 in Table 4 , 5ϫ10 5 immune LN cells no longer responded when 2ϫ10 4 peritoneal cells were added to them, or in other experiments, when small numbers of adherent cells recovered from normal spleens were used. Furthermore, as shown in Experiment 3 in Table 4 , anti-Fc receptor antibody at a concentration of 3 µg/ml of culture medium prevented suppression of normal spleen cells caused by immune LN cells. In other experiments aggregated rabbit IgG or murine antigen-antibody complexes formed in antibody excess, 50-100 µg of complexes/ml of culture medium, were as effective as anti-receptor antibody in preventing suppression caused by immune LN cells. Neither aggregated rabbit IgG nor antigen-antibody complexes altered CTL responses of control MLC (data not shown). The paradox noted above might occur because Fc receptors are blocked by antigen-antibody complexes produced in regionally immunized LN; however, suppression of CTL responses was produced in LN in vivo (Table 1) and work in progress indicates that the critical cell type required for suppression is present in LN but is not recovered during usual mechanical preparation of LN cells.
Supranatants from short-term cultures of IgG-secreting PFC prevent CTL responses
Supranatants were prepared from cultures of immune LN cells obtained 6 days after immunization with SRBC began. LN cells were washed multiple times in large volumes of medium to eliminate carry over of serum antibody or antigen. Cells were assayed for PFC and cultured, 10 7 cells/1.0 ml of medium without 2-mercaptoethanol and only 0.5 % FCS. Cellfree supranatants were harvested 24 h later and were assayed immediately for their effect on CTL responses in MLC by adding 10 to 100 µl supranatant per culture. Volumes and FCS concentrations were adjusted to 200 µl and 5% in all cultures. Cultures were assayed 4 days later. The suppressive capacity of supranatants in many repeated experiments correlated directly with the numbers of IgG-secreting PFC cultured. Supranatants of cultures containing Ͻ10,000 PFC caused no suppression, whereas 25-50 µl of supranatants of cultures containing~20,000-50,000 PFC/10 7 cells prevented CTL responses. Elimination of adherent and/or Thy-1 ϩ cells from immune LN cells increased the relative numbers of PFC cultured, usually~2 fold, and increased the capacity of supranatants obtained from these cells to suppress, e.g. as shown in Fig. 1(A) .
Other kinds of experiments also indicated that the capacity of supranatants to suppress was a direct function of the number of IgG-secreting PFC cultured. For example, cultures containing~38,000 IgG-secreting PFC/10 7 cells were cultured for 12 h and a first supranatant was collected. The harvested cells resuspended in fresh medium were re-assayed for PFC, and now containing only~8,000 IgG-secreting PFC/10 7 cells, were re-cultured for an additional 12 h when a second supranatant was collected. Supranatant from the first 12 h of culture prevented CTL responses at 50 µl/culture, whereas 100 µl of supranatant from the second 12 h of culture caused no suppression. Suppression caused by supranatants was comparable to suppression we had previously observed for hyperimmune sera (2) . For example, aliquots of fresh supranatants were absorbed on SRBC, horse red blood cells (v/v, 10 min at 5°C) or were passed through columns of Protein G or control columns as had been done previously using immune sera (2) . In repeated experiments 50-100 µl of untreated supranatant per culture abolished CTL responses whereas aliquots absorbed on SRBC or Protein G caused no suppression. Aliquots absorbed on horse red blood cells or on control columns were as suppressive as untreated supranatants. Furthermore, suppression caused by supranatants was completely reversed by antibody against TGF-β (e.g. Fig. 1B) . Also, in additional experiments, treating aliquots of supranatants by brief acidification (pH 2.0 for 30 min which activates and dissociates TGF-β from IgG) abolished the capacity of supranatants to cause suppression. Thus, suppression caused by supranatants was comparable to suppression caused by immune sera or IgG-secreting PFC. Since neither mouse serum factors nor accessory cells were required for producing suppressive supranatants, the inference was that PFC-secreting IgG also secreted IgG-TGF-β. The following observations support this possibility.
Detection of the latency-associated peptide of TGF-β in IgG captured from PFC
In many repeated experiments immune LN cells obtained from mice 6 days after beginning immunizations were cultured for 2 h on membranes coated either with gαmIgG or with control gIg. We consistently detected~2000 discrete foci of IgG/10 6 immune LN cells incubated on membranes coated with gαmIgG and developed using rαmIgG;~200 similar sized discrete foci were produced per 10 6 immune LN cells on membranes coated with gαmIgG and developed using rαP-TGF-β (Fig. 2) . For technical reasons we were unsuccessful in double staining for both IgG and latent TGF-β on the same membranes, but the foci of latent TGF-β developed using rαP-TGF-β almost certainly coincided with foci of IgG captured from PFC secreting both IgG and latent TGF-β since: (i) no foci of either IgG or latent TGF-β were produced on membranes coated with control gIg rather than gαmIgG, (ii) very rare foci of IgG and no foci of latent TGF-β were produced by normal LN cells on membranes coated with gαmIgG and (iii) no foci were produced when rαh ferritin antibodies were substituted for the rabbit antibodies against murine IgG or P-TGF-β.
Latent TGF-β was most likely detected only in those foci of IgG produced by cells secreting IgG maximally at the time the cells were isolated. This suggestion is consistent with observations that the duration of secretion of IgG by PFC is only a few hours and the rate of secretion by different PFC during this time must vary considerably since plaques produced in agarose or in chambers differ in size by a factor of 10 or more. At any rate, detecting latent TGF-β in discrete foci on membranes coated to capture IgG, but not on control membranes, strongly suggests that at least some B cells secreting IgG also secrete detectable amounts of latent TGF-β, which is captured because it is linked to IgG. Of course the foci technique does not indicate the nature of the linkage between IgG and latent TGF-β or whether the complexes in foci are indeed biologically active. However, the findings are consistent with the experiments using supranatants and provide strong evidence that B cells secreting IgG linked to latent TGF-β may prevent CTL responses. 
Discussion
Immune LN cells containing~300 IgG-secreting PFC prevented CTL responses in cultures of 500,000 syngeneic normal splenic responder cells. Neither Thy-1 ϩ cells, macrophages nor DC present in immune LN cells were required. The rapid rate and short duration of secretion of IgG by PFC precluded positive selection or appreciable enrichment for these cells; however, the strict correlation between the number of IgG-secreting PFC added to fresh MLC and suppression indicated that these cells were responsible. Remaining doubt was reduced by experiments showing that immune LN cells containing large numbers of IgG-secreting PFC and cultured briefly produced supranatants which prevented CTL responses in MLC. Thy-1 ϩ cells, macrophages, DC and serum factors were not required for producing suppressive supranatants, indicating that PFC secreted the factor causing suppression. The factor was most likely IgG linked to latent TGF-β since the capacity of supranatants to suppress was eliminated by adsorptions which removed IgG, by brief acidification which dissociated IgG and TGF-β or by antibody against active TGF-β. Furthermore, the latency-associated peptide of latent TGF-β was detected in some foci of IgG captured from isolated PFC.
Although not required for production of suppressive supranatants, small numbers of resident macrophages recovered from spleens or the peritoneal cavity of normal mice were necessary for suppression caused by PFC. Freshly isolated resting or resident macrophages do not synthesize TGF-β (2,15), although thioglycolate-elicited, lipopolysaccharideinduced macrophages produce active TGF-β after 3 days in culture (15) . Active TGF-β, however, must be present in cultures within the first 24 h to suppress CTL responses (2) . Therefore, IgG-TGF-β produced by PFC undoubtedly provided the source of TGF-β responsible for suppression. Many cell types, including B and T lymphocytes, secrete latent TGF-β and relatively high concentrations of latent TGF-β are present in normal plasma, serum or purified IgG (~1.0-10 ng acid activatable TGF-β/mg IgG). Many cell types, including B and T lymphocytes, express receptor complexes for TGF-β, but receptors only bind active TGF-β (the 25 kDa homodimer cleaved from the 110 kDa homodimer of latent TGF-β). Thus, the pleotrophic effects of TGF-β must be highly regulated by selective uptake of latent TGF-β, focal activation and direct delivery of active TGF-β to target cells.
Various cell types secrete latent TGF-β as a three-component complex consisting of a homodimer of TGF-β noncovalently associated with the homodimer of the latency-associated peptide which in turn is disulfide linked to a binding protein (16) (17) (18) (19) . Synthesis of the binding protein was necessary for optimal secretion of the latent complex (20, 21) . By analogy, the latency-associated peptide of TGF-β may be disulfide linked to an IgG during the phase of rapid secretion of IgG by PFC. Interestingly, the physical characteristics of IgG-TGF-β, based on size and lattice formation with the immunizing antigen indicate that IgG-TGF-β consists of two molecules of IgG and one molecule of latent TGF-β (unpublished). (We have tested many IgGs of known and unknown specificities and of various isotype secreted by myelomas and hybridomas. Although all preparations contaiñ 1.0-10.0 ng latent TGF-β/mg IgG, none caused suppression, apparently because the complexes do not have the critical conformation or configuration which complexes produced by rapidly secreting PFC have.) This configuration, analogous to that of antigen-antibody complexes formed in antibody excess, would account for selective uptake and cross-linking of Fc receptors present on macrophages or possibly recently antigen-activated CD8 ϩ cells (22) . In either case, focusing of uptake through Fc receptors and local activation would account for the remarkable biological effectiveness of IgG-TGF-β, which is 100 to 1000 times more effective in preventing CTL responses than an equivalent amount of active TGF-β which could be recovered from the complex (2).
IgG-secreting PFC enter the circulation and home to the bone marrow where the bulk of IgG is produced (13, 14) . Presumably, circulating B lymphocytes secreting IgG and IgG-TGF-β can also be recruited to sites of antigen deposition, either antigen specifically or non-specifically through adhesion molecules, e.g. VLA-4 and LFA-1 expressed at high levels by IgG-secreting B lymphocytes and complementary molecules, VCAM-1 and ICAM-1, expressed by various cell types responding directly to antigen or indirectly to cytokines released by antigen-stimulated cells (23) (24) (25) . The implication is that the capacity of an individual to respond with specific CTL can potentially be regulated by relatively few B lymphocytes secreting IgG-TGF-β locally before threshold levels of circulating IgG-TGF-β occur.
Assuming that comparable regulation of CTL by IgG-TGF-β occurs in humans, the findings are relevant for designing better procedures for selectively promoting or preventing CTL-mediated immunity. While IgG-TGF-β did not downregulate existing or ongoing CTL responses (2), we found that an absence of B lymphocytes or elimination of IgG responses in mice promoted more effective CTL-mediated tumor immunity (26, 27) . Possibly IgG-TGF-β produced early may reduce CTL responses to the same antigen when CTL recognized epitopes are weakly expressed or poorly presented by class I MHC. In so far as we know, CTL immunity, induced first or simultaneously, does not affect adversely antibody-mediated immunity. These considerations indicate that for immunizing normal individuals against a specific cancer or viral infection, CTL responses and memory should be stimulated before or at least simultaneously with B lymphocyte responses. However, the more important and immediate implication is that for individuals already bearing a cancer or chronically infected, e.g. patients HIV-positive or with AIDS, abrogating existing IgG-TGF-β suppression may be necessary before immunization with CTL-recognized epitopes can be successful. On the other hand, highly purified or 'synthesized' biologically effective IgG-TGF-β might be clinically useful for pretreating patients to prevent CTL responses to allografts or for preventing acute graft versus host disease. The findings that fresh immune sera given passively suppressed CTL responses encourages this suggestion (1) and it is reasonable to expect that IgG-TGF-β should be less toxic than immunosuppressive agents currently used. Thus, by understanding the biology of IgG-TGF-β and developing ways for producing and controlling it, effective new immune therapies may be possible.
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